{"id":688228,"date":"2022-09-22T16:09:41","date_gmt":"2022-09-22T20:09:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/"},"modified":"2022-09-22T16:09:41","modified_gmt":"2022-09-22T20:09:41","slug":"xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/","title":{"rendered":"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Sept.  22, 2022  (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET.<\/p>\n<p>A live webcast of the presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors &amp; Media section of the Xilio Therapeutics website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0CC-wpx4jaYkqPSkJtoTIXsfm72-kE8PiFcXgNgHdzJy8tni6BE7FBHlrtBpYDAPJRnOuffVAu9hRguf1KdzCJSsSCUZOFupTuCz5dbZbiE=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.xiliotx.com\/<\/a>. A replay of the webcast will be archived on the website for 30 days following the presentation.<\/p>\n<p>\n        <strong>About Xilio Therapeutics<\/strong>\n      <\/p>\n<p>Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effects, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including its clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, as well as its earlier pipeline, including XTX301, a tumor-selective IL-12. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0CC-wpx4jaYkqPSkJtoTIQ-pDtpg67s-V0zpbKnJfXKAF6eQQDFDWgfancyBOCe6swb8aRoqThV5K44tDVlY9g==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/xiliotx.com<\/a> and follow us on Twitter\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-3Tuxpmwfk08i8vMnN_ucqpGQYglZOM7dhrx8GB4VoAt9bJdrJbV69gqPx4k9Hs7-n6yNx3ZyKwmxamA2LhQyA9GjvWJogCs0_M2eoQohy9N_B1EtKKS73hr5l0DGbLsEPDqo2sVq10m2z1oFEbBsGblKlsiWuFAE_-k5Weqgcc05YbQ1mUKwkh_u2zpJp9zRBdKxyZaLzJlFIFZiVzX4lKP7pCzEY62duJu7BIxMjuDGxmT5KjG_t_-UksRPxcoMfi0xTm_jvvdg7OfGd-bZO3stGf8FZVpCUnrpujnegbpT8W6F-IDwmW08fZemQRIKSo-4LemJFfRNI-C0_uxJTtAVfobPANn3CJUoVOHg4gmI8CU8fGhWuy0DeV_vk1B\" rel=\"nofollow noopener\" target=\"_blank\">(<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6GGANYze1f0Xl376p-TCmwVDRQdUOMwkruzTDIE_3eggYe-dZyVYkhxZv7i2YMZN0I1CF2rgrT__O_vL7teZiA==\" rel=\"nofollow noopener\" target=\"_blank\">@xiliotx<\/a>) and LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vtpeEa5CPSrMyZ07SwEhryFFJIn-3Ksc8pmj7ejAkM5OZi2IMkb3r6jE-5ql0G55OiKh2DB9C18ypK53GpdOfIY9b1gzKXANSpDjlZs-1nol4kyFXBO2032zafzg7vWF97x0_d2CPjZDXq07PaXoyJef1t7nAjV8WdJYob-f-H4=\" rel=\"nofollow noopener\" target=\"_blank\">Xilio Therapeutics, Inc.<\/a>).<\/p>\n<p>\n        <strong>For Investor Inquiries:<\/strong><br \/>\n        <br \/>Myles Clouston<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7_uQl3xNEAgA-l3fbrlh3U6tjxOBQ6udGody-5Col-8gPb3z4AMjizbTkczZ0hBmpm4HnFjGAYIC1ofReD93pw2-TmFd3m8oz5DvZX9Ukqc=\" rel=\"nofollow noopener\" target=\"_blank\">investors@xiliotx.com<\/a>\u00a0<\/p>\n<p>\n        <strong>For Media Inquiries:\u202f<\/strong><br \/>\n        <br \/>Julissa Viana<br \/>Vice President, Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s-E-5kBjfWJdsog9sxHt7bqYYlZyKDz4fj9TSnSbRS0meJ80tKLZrGebzNFfkj3GHu2GsBcaA5ZGmj0W-NUE5g==\" rel=\"nofollow noopener\" target=\"_blank\">media@xiliotx.com<\/a>\u00a0<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGYyODlkN2QtNTI1Yi00N2VkLWFhY2UtZjlmMDQ3ZjIxNDczLTEyMjEzNTc=\/tiny\/Xilio-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET. A live webcast of the presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors &amp; Media section of the Xilio Therapeutics website at https:\/\/ir.xiliotx.com\/. A replay of the webcast will be archived on the website for 30 days following the presentation. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688228","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET. A live webcast of the presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors &amp; Media section of the Xilio Therapeutics website at https:\/\/ir.xiliotx.com\/. A replay of the webcast will be archived on the website for 30 days following the presentation. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the &hellip; Continue reading &quot;Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T20:09:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference\",\"datePublished\":\"2022-09-22T20:09:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\"},\"wordCount\":267,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\",\"name\":\"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=\",\"datePublished\":\"2022-09-22T20:09:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/","og_locale":"en_US","og_type":"article","og_title":"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET. A live webcast of the presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors &amp; Media section of the Xilio Therapeutics website at https:\/\/ir.xiliotx.com\/. A replay of the webcast will be archived on the website for 30 days following the presentation. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the &hellip; Continue reading \"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-22T20:09:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference","datePublished":"2022-09-22T20:09:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/"},"wordCount":267,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/","name":"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=","datePublished":"2022-09-22T20:09:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTAwMCM1MTY1MjUzIzIyMDk4MDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688228"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688228\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}